menu ☰
menu ˟

FDA committee recommends ADDYI approval to treat hypoactive sexual desire disorder in pre-menopause

05 Jun 2015
In an 18-to-6 vote at the FDA joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee, flibanserin was recommended for approval to treat hypoactive sexual desire disord...

Click here to view the full article which appeared in Endocrinology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.